RXRA and chronic myelogenous leukemia, BCR-ABL1 positive: Upon treatment with ligands specific to the downregulated NHRs in the imatinib-resistant CML cell lines, only RXRA ligand treatment showed improved sensitivity to IM in both cell lines.